ALL
MCID: LKM062
MIFTS: 69

Leukemia, Acute Lymphoblastic (ALL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Acute Lymphoblastic

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic:

Name: Leukemia, Acute Lymphoblastic 57 72 37
Acute Lymphoblastic Leukemia 12 73 20 58 6 15 17
Acute Lymphocytic Leukemia 73 20 58 42 70
All 57 12 20 58 72
B-Cell Acute Lymphoblastic Leukemia 36 29 17
Leukemia, Acute Lymphocytic, Susceptibility to, 1 57 13
Leukemia, Acute Lymphoblastic, Susceptibility to 29 6
Precursor Lymphoblastic Lymphoma/leukemia 12 17
Acute Lymphoblastic Leukaemia 12 15
Precursor Lymphoid Neoplasm 58 70
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 70
Precursor Cell Lymphoblastic Leukemia-Lymphoma 44
Precursor Cell Lymphoblastic Leukemia Lymphoma 70
Leukemia Acute Lymphoblastic B-Hyperdiploid 72
Childhood Acute Lymphoblastic Leukemia 72
Acute Lymphoblastic Leukemia/lymphoma 58
Leukemia B-Cell Acute Lymphoblastic 72
Leukemia T-Cell Acute Lymphoblastic 72
Leukemia, Acute Lymphoblastic, 3 72
Leukemia, Lymphocytic, Acute, L1 70
Leukemia Acute Lymphoblastic 1 72
Leukemia, Acute, Lymphoblastic 39
Leukemia, Acute Lymphocytic 1 57
Leukemia Acute Lymphocytic 1 72
Lymphoblastic Leukemia Acute 54
Acute Lymphocytic Leukaemia 12
Leukemia Acute Lymphocytic 72
All3 72
All1 72

Characteristics:

Orphanet epidemiological data:

58
acute lymphoblastic leukemia
Prevalence: 1-9/100000 (France),1-9/100000 (United States),1-5/10000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: any age;

HPO:

31
leukemia, acute lymphoblastic:
Inheritance somatic mutation polygenic inheritance


Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:9952
OMIM® 57 613065
KEGG 36 H00001
ICD9CM 34 204.0
MeSH 44 D054198
NCIt 50 C3167 C7055
SNOMED-CT 67 128822004
ICD10 32 C91.0 C91.00
ICD10 via Orphanet 33 C91.0
UMLS via Orphanet 71 C0023449
Orphanet 58 ORPHA513
SNOMED-CT via HPO 68 124975008 91857003
UMLS 70 C0023449 C0023452 C1335469 more

Summaries for Leukemia, Acute Lymphoblastic

MedlinePlus : 42 What is leukemia? Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job: White blood cells help your body fight infection Red blood cells deliver oxygen from your lungs to your tissues and organs Platelets help form clots to stop bleeding When you have leukemia, your bone marrow makes large numbers of abnormal cells. This problem most often happens with white blood cells. These abnormal cells build up in your bone marrow and blood. They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. What is acute lymphocytic leukemia (ALL)? Acute lymphocytic leukemia is a type of acute leukemia. It's also called ALL and acute lymphoblastic leukemia. "Acute" means that it usually gets worse quickly if it's not treated. ALL is the most common type of cancer in children. It can also affect adults. In ALL, the bone marrow makes too many lymphocytes, a type of white blood cell. These cells normally help your body fight infection. But in ALL, they are abnormal and cannot fight infection very well. They also crowd out the healthy cells, which can lead to infection, anemia, and easy bleeding. These abnormal cells can also spread to other parts of the body, including the brain and spinal cord. What causes acute lymphocytic leukemia (ALL)? ALL happens when there are changes in the genetic material (DNA) in bone marrow cells. The cause of these genetic changes is unknown. However, there are certain factors that raise your risk of ALL. Who is at risk for acute lymphocytic leukemia (ALL)? The factors that raise your risk of ALL include Being male Being white Being over age 70 Having had chemotherapy or radiation therapy Having been exposed to high levels of radiation Having certain genetic disorders, such as Down syndrome What are the symptoms of acute lymphocytic leukemia (ALL)? The signs and symptoms of ALL include Weakness or feeling tired Fever or night sweats Easy bruising or bleeding Petechiae, which are tiny red dots under the skin. They are caused by bleeding. Shortness of breath Weight loss or loss of appetite Pain in the bones or stomach Pain or feeling of fullness below the ribs Swollen lymph nodes - you may notice them as painless lumps in the neck, underarm, stomach, or groin Having had many infections How is acute lymphocytic leukemia (ALL) diagnosed? Your health care provider may use many tools to diagnose ALL and figure out which subtype you have: A physical exam A medical history Blood tests, such as Complete blood count (CBC) with differential Blood chemistry tests such as a basic metabolic panel (BMP), comprehensive metabolic panel (CMP), kidney function tests, liver function tests, and electrolyte panel Blood smear Bone marrow tests. There are two main types - bone marrow aspiration and bone marrow biopsy. Both tests involve removing a sample of bone marrow and bone. The samples are sent to a lab for testing. Genetic tests to look for gene and chromosome changes If you are diagnosed with ALL, you may have additional tests to see whether the cancer has spread. These include imaging tests and a lumbar puncture, which is a procedure to collect and test cerebrospinal fluid (CSF). What are the treatments for acute lymphocytic leukemia (ALL)? Treatments for ALL include Chemotherapy Radiation therapy Chemotherapy with stem cell transplant Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells Treatment is usually done in two phases: The goal of the first phase is to kill the leukemia cells in the blood and bone marrow. This treatment puts the leukemia into remission. Remission means that the signs and symptoms of cancer are reduced or have disappeared. The second phase is known as post-remission therapy. Its goal is to prevent a relapse (return) of the cancer. It involves killing any remaining leukemia cells that may not be active but could begin to regrow. Treatment during both phases also usually includes central nervous system (CNS) prophylaxis therapy. This therapy helps prevent the spread of leukemia cells to the brain and spinal cord. It may be high dose chemotherapy or chemotherapy injected into the spinal cord. It also sometimes includes radiation therapy. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Acute Lymphoblastic, also known as acute lymphoblastic leukemia, is related to childhood acute lymphocytic leukemia and leukemia, acute lymphoblastic 3, and has symptoms including angina pectoris, chest pain and bone pain. An important gene associated with Leukemia, Acute Lymphoblastic is PAX5 (Paired Box 5), and among its related pathways/superpathways are Transcriptional misregulation in cancer and MicroRNAs in cancer. The drugs Epirubicin and Morphine have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are acute lymphoblastic leukemia and neoplasm

Disease Ontology : 12 A acute leukemia that is characterized by over production of lymphoblasts.

GARD : 20 Acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell ). It may develop in children or adults. ALL spreads to the blood fairly quickly, and then may spread to other areas of the body such as the lymph nodes, liver, spleen, central nervous system, and testicles (in males). Signs and symptoms of ALL may include fever, easy bruising or bleeding, feeling tired, loss of appetite, pain in the bones or abdomen, and painless lumps in the neck, underarm, stomach, or groin. ALL is typically caused by random, non- inherited changes in the DNA of immature lymphocytes called lymphoblasts. However, some people may inherit a genetic susceptibility to developing ALL. The risk to develop ALL may also be increased by past treatment for cancer, and by having certain genetic conditions or syndromes. Having one or more risk factors does not mean that a person definitely will develop ALL. Treatment of ALL depends on the person's age, how advanced the cancer is, and whether certain genetic changes are found in cancer cells. Treatment options may involve systemic and/or intrathecal chemotherapy, radiation therapy, targeted therapy, and/or a stem cell transplant. Biologic therapy and chimeric antigen receptor (CAR) T-cell therapy are currently being studied as treatment options and may be used when other therapies are not working. The chance of recovery also depends on many factors. With treatment, about 98% of children with ALL go into remission, and 85% of those with first-time ALL are expected have no long-term complications. The chance of recovery for adults is not as high, as 20-40% of adults are cured with current treatments.

OMIM® : 57 Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a subtype of acute leukemia, a cancer of the white blood cells. Somatically acquired mutations in several genes have been identified in ALL lymphoblasts, cells in the early stages of differentiation. Germline variation in certain genes may also predispose to susceptibility to ALL (Trevino et al., 2009). (613065) (Updated 05-Apr-2021)

KEGG : 36 Acute lymphocytic leukemia (ALL) is a clonal stem cell malignancy of excessive lymphoblast proliferation. It is now understood that ALL and lymphoblastic lymphoma are the same disease entities at the morphologic and immunophenotypic levels and classified as either B- and T-cell lymphoblastic leukemia/lymphoma (B-ALL and T-ALL). In the case of B-ALL, numerous reports have demonstrated that recurring genetic abnormalities are associated with sufficiently unique clinical, immunophenotypic, and/or prognostic features so that they can be considered as distinct entities. The most common rearrangements observed in B-ALL are the t(12;21) (p13;q22) rearrangement resulting in expression of the ETV6-RUNX1 fusion (TEL-AML1); the t(1;19) (q23;p13) translocation that results in expression of the TCF3 (E2A) fusion partner, (also known as TCF3) TFPT-PBX1 fusion (E2A-PBX); the t(9;22) (q34;q11.2) "Philadelphia" chromosome resulting in expression of the BCR-ABL1 fusion; and rearrangements of MLL (also known as KMT2A) at 11q23 to a diverse array of fusion partners. If none of these specific genetic abnormalities are found, the designation of "B lymphoblastic leukemia/lymphoma, not otherwise specified," is appropriate.

UniProtKB/Swiss-Prot : 72 Leukemia, acute lymphoblastic: A subtype of acute leukemia, a cancer of the white blood cells. ALL is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.
Leukemia, acute lymphoblastic, 3: A subtype of acute leukemia, a cancer of the white blood cells. Acute lymphoblastic anemia is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.

Wikipedia : 73 Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the... more...

Related Diseases for Leukemia, Acute Lymphoblastic

Diseases in the Leukemia, Acute Lymphoblastic family:

Leukemia, Acute Lymphoblastic 2 Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1331)
# Related Disease Score Top Affiliating Genes
1 childhood acute lymphocytic leukemia 34.4 PAX5 NBN GNB1 FLT3 ETV6 ACTB
2 leukemia, acute lymphoblastic 3 33.5 PAX5 FLT3 ETV6
3 childhood b-cell acute lymphoblastic leukemia 33.2 PAX5 CRLF2
4 lymphoblastic leukemia, acute, with lymphomatous features 32.9 JAK2 INSL6 CRLF2
5 b-lymphoblastic leukemia/lymphoma 32.6 PAX5 FLT3 ETV6
6 myeloproliferative neoplasm 32.0 MIR155 JAK2 INSL6 FLT3 ETV6
7 myelofibrosis 32.0 JAK2 INSL6 FLT3 ETV6 CDKN2B-AS1
8 adult acute lymphocytic leukemia 31.8 PAX5 ETV6 CRLF2
9 down syndrome 31.8 MIR155 JAK2 ETV6 CRLF2
10 lymphoma, non-hodgkin, familial 31.8 PAX5 NBN MIR155 JAK2 FLT3 ETV6
11 leukemia 31.6 PAX5 JAK2 FLT3 ETV6 CRLF2 CDKN2B-AS1
12 leukemia, chronic lymphocytic 31.6 PAX5 MIR155 JAK2 GNB1 FLT3
13 b-lymphoblastic leukemia/lymphoma with iamp21 31.4 PAX5 ETV6 CRLF2
14 etv6 thrombocytopenia and predisposition to leukemia 31.4 JAK2 FLT3 ETV6
15 hematologic cancer 31.4 XIST PAX5 MIR335 MIR196B MIR155 JAK2
16 myeloma, multiple 31.4 MIR335 JAK2 FLT3 ACTB
17 leukemia, acute monocytic 31.4 MIR155 FLT3 ACTB
18 lymphoma, hodgkin, classic 31.4 PAX5 MIR155 JAK2
19 retinitis pigmentosa 11 31.3 XIST MIR335 ETV6 ACTB
20 leukemia, acute myeloid 31.3 PAX5 MIR335 MIR155 JAK2 INSL6 FLT3
21 atypical chronic myeloid leukemia 31.1 JAK2 FLT3 ETV6
22 acute megakaryocytic leukemia 31.0 JAK2 FLT3 ETV6
23 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.9 FLT3 ETV6
24 acute leukemia 30.9 PAX5 JAK2 FLT3 ETV6
25 myelodysplastic/myeloproliferative neoplasm 30.9 JAK2 FLT3 ETV6
26 chronic eosinophilic leukemia 30.9 JAK2 FLT3 ETV6
27 childhood t-cell acute lymphoblastic leukemia 11.7
28 leukemia, acute lymphoblastic 2 11.6
29 b-cell adult acute lymphocytic leukemia 11.6
30 null-cell leukemia 11.4
31 acute lymphoblastic leukemia congenital sporadic aniridia 11.3
32 medulloblastoma 11.2
33 b-lymphoblastic leukemia/lymphoma with tcf3-pbx1 11.2
34 t-cell adult acute lymphocytic leukemia 11.2
35 t-cell acute lymphoblastic leukemia 11.2
36 pdgfra-associated chronic eosinophilic leukemia 11.2
37 childhood leukemia 11.0
38 hypereosinophilic syndrome 10.8
39 neutropenia 10.8
40 mental retardation, autosomal dominant 33 10.8 PAX5 JAK2 ETV6 CRLF2
41 aspergillosis 10.7
42 bone marrow cancer 10.7 JAK2 INSL6 FLT3 ETV6
43 cebpa-associated familial acute myeloid leukemia 10.7 JAK2 FLT3 ETV6
44 hepatic veno-occlusive disease 10.7
45 osteonecrosis 10.7
46 leiomyoma, uterine 10.6 MIR335 MIR203A MIR196B
47 chromosomal triplication 10.6
48 splenomegaly 10.6
49 chromosomal duplication syndrome 10.6 MIR155 ETV6 CRLF2
50 interleukin-7 receptor alpha deficiency 10.6

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic:



Diseases related to Leukemia, Acute Lymphoblastic

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic

Human phenotypes related to Leukemia, Acute Lymphoblastic:

31
# Description HPO Frequency HPO Source Accession
1 acute lymphoblastic leukemia 31 HP:0006721

Clinical features from OMIM®:

613065 (Updated 05-Apr-2021)

UMLS symptoms related to Leukemia, Acute Lymphoblastic:


angina pectoris; chest pain; bone pain; edema

MGI Mouse Phenotypes related to Leukemia, Acute Lymphoblastic:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 ACTB ETV6 FLT3 JAK2 NBN PAX5

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic

Drugs for Leukemia, Acute Lymphoblastic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 490)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4 56420-45-2 41867
2
Morphine Approved, Investigational Phase 4 57-27-2 5288826
3
Nicotine Approved Phase 4 54-11-5 942 89594
4
Teniposide Approved Phase 4 29767-20-2 34698
5
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
6
Oprelvekin Approved, Investigational Phase 4 145941-26-0
7
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
8
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
9
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
10
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
11
Ethylene Phase 4 74-85-1 6325
12 Calciferol Phase 4
13 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
14 Hydroxycholecalciferols Phase 4
15 Vitamin D2 Phase 4
16 Ergocalciferols Phase 4
17 Neurotransmitter Agents Phase 4
18 Adrenergic Agents Phase 4
19 Atomoxetine Hydrochloride Phase 4
20
Pentoxifylline Approved, Investigational Phase 2, Phase 3 6493-05-6 4740
21
Lorazepam Approved Phase 3 846-49-1 3958
22
Erythromycin Approved, Investigational, Vet_approved Phase 2, Phase 3 114-07-8 12560
23
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
24
Calcium carbonate Approved, Investigational Phase 3 471-34-1
25
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
26
Methylcobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
27
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
28
Chlorhexidine Approved, Vet_approved Phase 3 55-56-1 2713 9552079
29
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
30
Enalaprilat Approved Phase 3 76420-72-9 6917719
31
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
32
Ofloxacin Approved Phase 3 82419-36-1 4583
33
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
34
Etidronic acid Approved Phase 3 7414-83-7, 2809-21-4 3305
35
Risedronate Approved, Investigational Phase 3 105462-24-6 5245
36
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
38
Daunorubicin Approved Phase 3 20830-81-3 30323
39
rituximab Approved Phase 3 174722-31-7 10201696
40
Thioguanine Approved Phase 3 154-42-7 2723601
41
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
42
Ifosfamide Approved Phase 3 3778-73-2 3690
43
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
44
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
45
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
46
Azathioprine Approved Phase 3 446-86-6 2265
47
Apixaban Approved Phase 3 503612-47-3 10182969
48
Abatacept Approved Phase 3 332348-12-6 10237
49
Amsacrine Approved, Investigational Phase 2, Phase 3 51264-14-3 2179
50
Mycophenolic acid Approved Phase 3 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 1597)
# Name Status NCT ID Phase Drugs
1 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
2 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
3 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
4 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
5 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
6 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
7 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
8 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
9 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
10 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
11 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
12 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Unknown status NCT03558412 Phase 4 Decitabine
13 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
14 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
15 Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
16 German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
17 Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
18 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
19 Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
20 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
21 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
22 Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
23 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Completed NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
24 Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study Completed NCT02447718 Phase 4
25 LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
26 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
27 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4 Prednisone;Vincristine;Daunorubicin;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside;Mercaptopurine;VP-16
28 Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
29 The Study on the Pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor(PEG-rhG-CSF) in Children and Adolescents Completed NCT02953730 Phase 4 PEG-rhG-CSF
30 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Completed NCT03176849 Phase 4
31 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
32 Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
33 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
34 A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE Recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
35 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4 Imatinib
36 PROTOCOL FOR THE TREATMENT Acute Lymphoblastic Leukemia With Ph 'NEGATIVE IN ELDERLY PATIENTS (> 55 Years) Recruiting NCT01366898 Phase 4 Dexamethasona, Idarubicine, ARA-C, Methotrexate
37 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
38 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
39 Treatment Protocol For All Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4 vINCRISTINE;Dexamethasone;Methotrexate;Cytosine arabinoside
40 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
41 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Enrolling by invitation NCT03920813 Phase 4 Mercaptopurine
42 A Phase 4, Multi-center Open-label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission Not yet recruiting NCT04506086 Phase 4 Blinatumomab
43 ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
44 Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for Acute Lymphocytic Leukemia Terminated NCT00299234 Phase 4 Atomoxetine
45 Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults Unknown status NCT00131027 Phase 3 Cyclophosphamide;Daunorubicin;Vincristine;Prednisolone;L-asparaginase;Cytarabine;Etoposide;Dexamethasone;Methotrexate;Mercaptopurine;Doxorubicin;Methotrexate
46 A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation Unknown status NCT00450450 Phase 3
47 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma Unknown status NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
48 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
49 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
50 A Phase-2 Clinical Study to Determine the Efficacy and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of CNS Relapse in Adult Patients With Acute Lymphoblastic Leukemia or Very Aggressive Lymphoma Unknown status NCT00199108 Phase 2, Phase 3 Depocyt;Dexamethasone

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic

Inferred drug relations via UMLS 70 / NDF-RT 51 :


ASPARAGINASE
Cyclophosphamide
Idarubicin
Idarubicin Hydrochloride
Ifosfamide
mercaptopurine
pegaspargase
sargramostim

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Lymphoblastic cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: precursor cell lymphoblastic leukemia-lymphoma

Genetic Tests for Leukemia, Acute Lymphoblastic

Genetic tests related to Leukemia, Acute Lymphoblastic:

# Genetic test Affiliating Genes
1 Leukemia, Acute Lymphoblastic, Susceptibility to 29
2 B-Cell Acute Lymphoblastic Leukemia 29

Anatomical Context for Leukemia, Acute Lymphoblastic

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic:

40
Bone Marrow, T Cells, Myeloid, Bone, Spinal Cord, Spleen, Breast
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Lymphoblastic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease

Publications for Leukemia, Acute Lymphoblastic

Articles related to Leukemia, Acute Lymphoblastic:

(show top 50) (show all 27187)
# Title Authors PMID Year
1
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. 57 6 61
19838194 2009
2
FLT3 mutations in childhood acute lymphoblastic leukemia. 61 57 6
14670924 2004
3
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. 61 54 6
19965641 2010
4
Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. 6 54 61
19139102 2009
5
First case of aplastic anemia in a Japanese child with a homozygous missense mutation in the NBS1 gene (I171V) associated with genomic instability. 61 54 6
15338273 2004
6
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. 6 61
30643249 2019
7
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. 61 57
24413735 2014
8
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. 61 57
24076604 2013
9
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. 6 61
24013638 2013
10
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. 61 57
23263491 2013
11
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. 6 61
22772060 2013
12
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. 61 6
22955920 2012
13
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. 61 6
22897847 2012
14
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. 6 61
22368272 2012
15
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. 61 57
22237151 2012
16
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. 57 61
21892159 2011
17
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. 61 6
21680795 2011
18
ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. 6 54
20167706 2010
19
PHF6 mutations in T-cell acute lymphoblastic leukemia. 61 57
20228800 2010
20
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. 61 57
20042726 2010
21
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. 6 61
20018760 2010
22
Germline genomic variants associated with childhood acute lymphoblastic leukemia. 57 61
19684603 2009
23
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. 61 57
19684604 2009
24
JAK mutations in high-risk childhood acute lymphoblastic leukemia. 61 6
19470474 2009
25
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. 6 61
18615627 2008
26
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. 61 57
15361874 2004
27
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. 61 6
11861307 2002
28
Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). 61 6
11325820 2001
29
Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. 57 61
9531611 1998
30
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. 61 42
33651090 2021
31
Leukaemia hijacks a neural mechanism to invade the central nervous system. 57
30022166 2018
32
Histidine catabolism is a major determinant of methotrexate sensitivity. 57
29995852 2018
33
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. 57
29342136 2018
34
Metabolic gatekeeper function of B-lymphoid transcription factors. 57
28192788 2017
35
Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures. 6
27108799 2016
36
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
37
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. 6
25485910 2015
38
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
39
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. 57
25132549 2014
40
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. 57
25043004 2014
41
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. 6
22368270 2012
42
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. 57
22237106 2012
43
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. 6
20372971 2011
44
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. 57
21593872 2011
45
CREBBP mutations in relapsed acute lymphoblastic leukaemia. 57
21390130 2011
46
Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. 61 47
21116279 2011
47
Genetic variegation of clonal architecture and propagating cells in leukaemia. 57
21160474 2011
48
Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. 6
19907440 2010
49
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. 47 61
18923441 2009
50
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. 6
18805579 2008

Variations for Leukemia, Acute Lymphoblastic

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic:

6 (show top 50) (show all 59)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IKZF1 NM_006060.6(IKZF1):c.*2279T>G SNV association 694328 rs4132601 GRCh37: 7:50470604-50470604
GRCh38: 7:50402906-50402906
2 IKZF1 NM_006060.6(IKZF1):c.851-1312A>G SNV association 691984 rs11978267 GRCh37: 7:50466304-50466304
GRCh38: 7:50398606-50398606
3 JAK2 , INSL6 NM_004972.3(JAK2):c.2049A>T (p.Arg683Ser) SNV Pathogenic 375954 rs1057519723 GRCh37: 9:5078362-5078362
GRCh38: 9:5078362-5078362
4 JAK2 , INSL6 NM_004972.3(JAK2):c.2047A>G (p.Arg683Gly) SNV Pathogenic 375951 rs1057519721 GRCh37: 9:5078360-5078360
GRCh38: 9:5078360-5078360
5 JAK2 , INSL6 NM_004972.3(JAK2):c.2049A>C (p.Arg683Ser) SNV Pathogenic 375953 rs1057519723 GRCh37: 9:5078362-5078362
GRCh38: 9:5078362-5078362
6 CRLF2 NM_022148.4(CRLF2):c.695T>G (p.Phe232Cys) SNV Pathogenic 376003 rs1057519743 GRCh37: Y:1264966-1264966
GRCh38: X:1196852-1196852
7 NBN NM_002485.4(NBN):c.1903A>T (p.Lys635Ter) SNV Pathogenic 142559 rs587782545 GRCh37: 8:90960063-90960063
GRCh38: 8:89947835-89947835
8 NBN NM_002485.4(NBN):c.1030C>T (p.Gln344Ter) SNV Pathogenic 190229 rs767215758 GRCh37: 8:90971047-90971047
GRCh38: 8:89958819-89958819
9 GNB1 NM_002074.5(GNB1):c.239T>A (p.Ile80Asn) SNV Pathogenic 224715 rs752746786 GRCh37: 1:1737942-1737942
GRCh38: 1:1806503-1806503
10 GNB1 NM_002074.5(GNB1):c.227A>G (p.Asp76Gly) SNV Pathogenic 224711 rs869312821 GRCh37: 1:1737954-1737954
GRCh38: 1:1806515-1806515
11 ACTB NP_001092.1(ACTB):p.Val209Leu protein only Pathogenic 218133 GRCh37:
GRCh38:
12 PAX5 P80R Variation Pathogenic 624590 GRCh37:
GRCh38:
13 JAK2 , INSL6 NM_004972.3(JAK2):c.2048G>C (p.Arg683Thr) SNV Pathogenic 375952 rs1057519722 GRCh37: 9:5078361-5078361
GRCh38: 9:5078361-5078361
14 ETV6 NM_001987.4(ETV6):c.1046T>C (p.Leu349Pro) SNV Pathogenic 190241 rs786205155 GRCh37: 12:12037415-12037415
GRCh38: 12:11884481-11884481
15 ETV6 NM_001987.4(ETV6):c.1153-5_1153-1del Microsatellite Pathogenic 190240 GRCh37: 12:12038855-12038859
GRCh38: 12:11885921-11885925
16 FLT3 NM_004119.3(FLT3):c.1777_1779del (p.Asp593del) Deletion Pathogenic 16278 rs587776834 GRCh37: 13:28608277-28608279
GRCh38: 13:28034140-28034142
17 FLT3 NM_004119.3(FLT3):c.2503G>T (p.Asp835Tyr) SNV Pathogenic 16276 rs121913488 GRCh37: 13:28592642-28592642
GRCh38: 13:28018505-28018505
18 FLT3 NM_004119.3(FLT3):c.2504A>T (p.Asp835Val) SNV Pathogenic 16272 rs121909646 GRCh37: 13:28592641-28592641
GRCh38: 13:28018504-28018504
19 NBN NM_002485.4(NBN):c.2140C>T (p.Arg714Ter) SNV Likely pathogenic 182737 rs730881864 GRCh37: 8:90955525-90955525
GRCh38: 8:89943297-89943297
20 JAK3 NM_000215.3(JAK3):c.394C>A (p.Pro132Thr) SNV Likely pathogenic 134580 rs3212723 GRCh37: 19:17954215-17954215
GRCh38: 19:17843406-17843406
21 JAK3 NM_000215.3(JAK3):c.2164G>A (p.Val722Ile) SNV Likely pathogenic 134573 rs3213409 GRCh37: 19:17945696-17945696
GRCh38: 19:17834887-17834887
22 FGFR1 NM_015850.4(FGFR1):c.1962G>C (p.Lys654Asn) SNV Likely pathogenic 376428 rs1057519897 GRCh37: 8:38272306-38272306
GRCh38: 8:38414788-38414788
23 FGFR1 NM_023110.2(FGFR1):c.1966A>G (p.Lys656Glu) SNV Likely pathogenic 224897 rs869320694 GRCh37: 8:38272308-38272308
GRCh38: 8:38414790-38414790
24 PAX5 NM_016734.3(PAX5):c.547G>A (p.Gly183Ser) SNV risk factor 88892 rs398123063 GRCh37: 9:37002702-37002702
GRCh38: 9:37002705-37002705
25 NBN NM_002485.5(NBN):c.511A>G (p.Ile171Val) SNV risk factor 6946 rs61754966 GRCh37: 8:90990521-90990521
GRCh38: 8:89978293-89978293
26 ABL1 NM_005157.6(ABL1):c.944C>T (p.Thr315Ile) SNV Likely pathogenic 12624 rs121913459 GRCh37: 9:133748283-133748283
GRCh38: 9:130872896-130872896
27 NBN NM_001024688.2(NBN):c.345_357delinsTTG (p.Pro116fs) Indel Likely pathogenic 481871 rs1554564297 GRCh37: 8:90983500-90983512
GRCh38: 8:89971272-89971284
28 NBN NM_001024688.2(NBN):c.-141_-140del Deletion Likely pathogenic 371121 rs767454740 GRCh37: 8:90994964-90994965
GRCh38: 8:89982736-89982737
29 ABL1 NM_005157.6(ABL1):c.757T>C (p.Tyr253His) SNV Likely pathogenic 12627 rs121913461 GRCh37: 9:133738357-133738357
GRCh38: 9:130862970-130862970
30 JAK1 NM_002227.4(JAK1):c.1937C>T (p.Ser646Phe) SNV Likely pathogenic 376099 rs151047872 GRCh37: 1:65312382-65312382
GRCh38: 1:64846699-64846699
31 IL7R NM_002185.5(IL7R):c.553A>T (p.Ser185Cys) SNV Likely pathogenic 376098 rs1057519759 GRCh37: 5:35873597-35873597
GRCh38: 5:35873495-35873495
32 JAK1 NM_002227.4(JAK1):c.1972G>T (p.Val658Phe) SNV Likely pathogenic 376030 rs1057519753 GRCh37: 1:65312347-65312347
GRCh38: 1:64846664-64846664
33 JAK1 NM_002227.4(JAK1):c.1901C>A (p.Ala634Asp) SNV Likely pathogenic 225075 rs869312953 GRCh37: 1:65312418-65312418
GRCh38: 1:64846735-64846735
34 NBN NM_002485.4(NBN):c.683T>G (p.Ile228Arg) SNV Uncertain significance 186350 rs777460725 GRCh37: 8:90983420-90983420
GRCh38: 8:89971192-89971192
35 NBN NM_002485.4(NBN):c.505C>T (p.Arg169Cys) SNV Uncertain significance 127873 rs182756889 GRCh37: 8:90990527-90990527
GRCh38: 8:89978299-89978299
36 NBN NM_002485.4(NBN):c.431C>T (p.Thr144Ile) SNV Uncertain significance 485924 rs1554567906 GRCh37: 8:90993011-90993011
GRCh38: 8:89980783-89980783
37 NBN NM_002485.5(NBN):c.119C>T (p.Ser40Leu) SNV Uncertain significance 141146 rs587781530 GRCh37: 8:90995002-90995002
GRCh38: 8:89982774-89982774
38 NBN NM_002485.4(NBN):c.595C>T (p.Pro199Ser) SNV Uncertain significance 127874 rs587780097 GRCh37: 8:90983508-90983508
GRCh38: 8:89971280-89971280
39 PAX5 NM_016734.3(PAX5):c.1013-1G>A SNV Uncertain significance 517139 rs1554646594 GRCh37: 9:36846927-36846927
GRCh38: 9:36846930-36846930
40 PAX5 NM_016734.3(PAX5):c.435G>C (p.Gln145His) SNV Uncertain significance 587563 rs758368747 GRCh37: 9:37006510-37006510
GRCh38: 9:37006513-37006513
41 NBN NM_002485.4(NBN):c.361G>C (p.Asp121His) SNV Uncertain significance 231708 rs777916019 GRCh37: 8:90993081-90993081
GRCh38: 8:89980853-89980853
42 NBN NM_002485.4(NBN):c.260T>C (p.Phe87Ser) SNV Uncertain significance 187236 rs786203573 GRCh37: 8:90993663-90993663
GRCh38: 8:89981435-89981435
43 NBN NM_002485.5(NBN):c.1262T>C (p.Leu421Ser) SNV Uncertain significance 127009 rs104895032 GRCh37: 8:90967646-90967646
GRCh38: 8:89955418-89955418
44 NBN NM_002485.5(NBN):c.425A>G (p.Asn142Ser) SNV Uncertain significance 127871 rs769414 GRCh37: 8:90993017-90993017
GRCh38: 8:89980789-89980789
45 NBN NM_002485.5(NBN):c.2215C>G (p.Leu739Val) SNV Uncertain significance 182730 rs370058152 GRCh37: 8:90949273-90949273
GRCh38: 8:89937045-89937045
46 NBN NM_002485.4(NBN):c.2149A>T (p.Thr717Ser) SNV Uncertain significance 127865 rs587780093 GRCh37: 8:90955516-90955516
GRCh38: 8:89943288-89943288
47 NBN NM_002485.4(NBN):c.775G>A (p.Glu259Lys) SNV Uncertain significance 182716 rs201559159 GRCh37: 8:90982713-90982713
GRCh38: 8:89970485-89970485
48 NBN NM_002485.4(NBN):c.503G>A (p.Gly168Glu) SNV Uncertain significance 461570 rs1554566728 GRCh37: 8:90990529-90990529
GRCh38: 8:89978301-89978301
49 NBN NM_002485.4(NBN):c.340G>T (p.Val114Phe) SNV Uncertain significance 219644 rs771034958 GRCh37: 8:90993102-90993102
GRCh38: 8:89980874-89980874
50 NBN NM_002485.5(NBN):c.511A>G (p.Ile171Val) SNV Uncertain significance 6946 rs61754966 GRCh37: 8:90990521-90990521
GRCh38: 8:89978293-89978293

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Lymphoblastic:

72
# Symbol AA change Variation ID SNP ID
1 PAX5 p.Gly183Ser VAR_070682 rs398123063

Copy number variations for Leukemia, Acute Lymphoblastic from CNVD:

7 (show top 50) (show all 2943)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13316 1 1 117600000 Loss Acute lymphoblastic leukemia
2 13371 17 1 22200000 Deletion TP53 Acute lymphoblastic leukemia
3 13773 1 1 35400000 Duplication Acute lymphoblastic leukemia
4 13788 1 1 40300000 Duplication Acute lymphoblastic leukemia
5 13790 1 1 46500000 Gain Acute lymphoblastic leukemia
6 13836 12 10000000 12600000 Deletion ETV6 Acute lymphoblastic leukemia
7 13906 1 100818677 103024856 Loss DPH5 Acute lymphoblastic leukemia
8 13907 1 100818677 103024856 Loss EXTL2 Acute lymphoblastic leukemia
9 13908 1 100818677 103024856 Loss OLFM3 Acute lymphoblastic leukemia
10 13909 1 100818677 103024856 Loss S1PR1 Acute lymphoblastic leukemia
11 13910 1 100818677 103024856 Loss SLC30A7 Acute lymphoblastic leukemia
12 13911 1 100818677 103024856 Loss VCAM1 Acute lymphoblastic leukemia
13 13991 1 102370195 102561809 Deletion Acute lymphoblastic leukemia
14 14292 1 106673274 107678605 Loss NTNG1 Acute lymphoblastic leukemia
15 14293 1 106673274 107678605 Loss PRMT6 Acute lymphoblastic leukemia
16 14369 1 107716342 144004701 Loss ADAM30 Acute lymphoblastic leukemia
17 14370 1 107716342 144004701 Loss ADORA3 Acute lymphoblastic leukemia
18 14371 1 107716342 144004701 Loss AKR7A2P1 Acute lymphoblastic leukemia
19 14372 1 107716342 144004701 Loss AHCYL1 Acute lymphoblastic leukemia
20 14373 1 107716342 144004701 Loss AKNAD1 Acute lymphoblastic leukemia
21 14374 1 107716342 144004701 Loss ALX3 Acute lymphoblastic leukemia
22 14375 1 107716342 144004701 Loss AMIGO1 Acute lymphoblastic leukemia
23 14376 1 107716342 144004701 Loss AMPD1 Acute lymphoblastic leukemia
24 14377 1 107716342 144004701 Loss AMPD2 Acute lymphoblastic leukemia
25 14378 1 107716342 144004701 Loss AP4B1 Acute lymphoblastic leukemia
26 14379 1 107716342 144004701 Loss ATP1A1 Acute lymphoblastic leukemia
27 14380 1 107716342 144004701 Loss ATP5PB Acute lymphoblastic leukemia
28 14381 1 107716342 144004701 Loss ATXN7L2 Acute lymphoblastic leukemia
29 14382 1 107716342 144004701 Loss BCAS2 Acute lymphoblastic leukemia
30 14383 1 107716342 144004701 Loss BCL2L15 Acute lymphoblastic leukemia
31 14384 1 107716342 144004701 Loss LRIF1 Acute lymphoblastic leukemia
32 14385 1 107716342 144004701 Loss PFN1P2 Acute lymphoblastic leukemia
33 14386 1 107716342 144004701 Loss MAB21L3 Acute lymphoblastic leukemia
34 14387 1 107716342 144004701 Loss C1orf162 Acute lymphoblastic leukemia
35 13410 1 1 2300000 Copy number Acute lymphoblastic leukemia
36 14388 1 107716342 144004701 Loss INKA2 Acute lymphoblastic leukemia
37 15383 1 115048600 115061038 Copy number NRAS Acute lymphoblastic leukemia
38 15429 1 115400000 222100000 Gain Acute lymphoblastic leukemia
39 15832 1 119869201 120436800 Loss HMGCS2 Acute lymphoblastic leukemia
40 15833 1 119869201 120436800 Loss NBPF7P Acute lymphoblastic leukemia
41 15834 1 119869201 120436800 Loss NOTCH2 Acute lymphoblastic leukemia
42 15835 1 119869201 120436800 Loss PHGDH Acute lymphoblastic leukemia
43 15836 1 119869201 120436800 Loss REG4 Acute lymphoblastic leukemia
44 15837 1 119869201 120436800 Loss ZNF697 Acute lymphoblastic leukemia
45 15979 1 120700000 169100000 Loss CREG1 Acute lymphoblastic leukemia
46 16426 1 124300000 247249719 Deletion Acute lymphoblastic leukemia
47 16427 1 124300000 247249719 Duplication Acute lymphoblastic leukemia
48 16474 1 125000000 249250621 Copy number Acute lymphoblastic leukemia
49 16502 1 12600000 16100000 Deletion Acute lymphoblastic leukemia
50 16592 1 128000000 185104377 Copy number Acute lymphoblastic leukemia

Expression for Leukemia, Acute Lymphoblastic

Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic.

Pathways for Leukemia, Acute Lymphoblastic

Pathways related to Leukemia, Acute Lymphoblastic according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.42 MIR335 MIR203A MIR155 MIR152
2 10.3 FLT3 ETV6

GO Terms for Leukemia, Acute Lymphoblastic

Biological processes related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.35 MIR335 MIR203A MIR196B MIR155 MIR152
2 dendritic cell differentiation GO:0097028 9.16 MIR155 FLT3
3 negative regulation of cytokine production involved in inflammatory response GO:1900016 8.8 MIR203A MIR155 MIR152

Sources for Leukemia, Acute Lymphoblastic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....